Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA,KRASandBRAFin the plasma

Intra-tumoral Heterogeneity ofKRASandBRAFMutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

(2015) Susan D. Richman et al.   Analytical Cellular Pathology

Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial

(2013) Clemens Giessen et al.   CANCER SCIENCE

Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

(2012) K.-L. G. Spindler et al.   CLINICAL CANCER RESEARCH

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

(2012) Kjell Magne Tveit et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

(2011) N Knijn et al.   BRITISH JOURNAL OF CANCER

Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors

(2011) Teodora Evgenieva Goranova et al.   CLINICAL & EXPERIMENTAL METASTASIS

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Timothy S Maughan et al.   LANCET

KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications

(2010) Antoine Italiano et al.   ANNALS OF SURGICAL ONCOLOGY

Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis

(2010) Mohamed Bouchahda et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer

(2010) Helena Linardou et al.   CANCER TREATMENT REVIEWS

Cell-free DNA in the blood as a solid tumor biomarker—A critical appraisal of the literature

(2010) Klaus Jung et al.   CLINICA CHIMICA ACTA

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies

(2010) Li-Xin Qiu et al.   EUROPEAN JOURNAL OF CANCER

Patient With Colorectal Cancer With HeterogeneousKRASMolecular Status Responding to Cetuximab-Based Chemotherapy

(2010) Andrea Mancuso et al.   JOURNAL OF CLINICAL ONCOLOGY

A mathematical framework to determine the temporal sequence of somatic genetic events in cancer

(2010) Camille Stephan-Otto Attolini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer

(2009) K. -L. Garm Spindler et al.   ANNALS OF ONCOLOGY

Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?

(2009) Maniesh van der Vaart et al.   CLINICAL BIOCHEMISTRY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

(2008) D. Santini et al.   ONCOLOGIST

Characterization of circulating DNA in healthy human plasma

(2007) Nobuyasu Suzuki et al.   CLINICA CHIMICA ACTA